XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:    
Total revenue $ 96,844,000 $ 82,422,000
Operating expenses:    
Research and development 15,965,000 12,769,000
Selling and marketing 23,782,000 26,130,000
General and administrative 26,210,000 21,053,000
Impairment of long-lived assets 429,000 1,410,000
Intangible asset amortization 3,653,000 5,329,000
Total operating expenses 101,500,000 92,920,000
Loss from operations (4,656,000) (10,498,000)
Other income, net 2,748,000 2,407,000
Loss before income taxes (1,908,000) (8,091,000)
Income tax benefit (44,000) 0
Net loss $ (1,864,000) $ (8,091,000)
Net loss per common share, basic (in USD per share) $ (0.02) $ (0.11)
Net loss per common share, diluted (in USD per share) $ (0.02) $ (0.11)
Shares used to compute net loss per common share, basic (in shares) 74,759,789 72,175,457
Shares used to compute net loss per common share, diluted (in shares) 74,759,789 72,175,457
Testing revenue    
Revenue:    
Total revenue $ 90,303,000 $ 72,396,000
Operating expenses:    
Cost of revenue 25,979,000 19,648,000
Product revenue    
Revenue:    
Total revenue 3,537,000 3,892,000
Operating expenses:    
Cost of revenue 2,644,000 2,162,000
Biopharmaceutical and other revenue    
Revenue:    
Total revenue 3,004,000 6,134,000
Operating expenses:    
Cost of revenue $ 2,838,000 $ 4,419,000